Replimune Group Inc (NASDAQ:REPL) Receives $24.50 Consensus PT from Brokerages

Shares of Replimune Group Inc (NASDAQ:REPL) have been assigned an average rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $24.50.

Several equities analysts have recently issued reports on the company. Wedbush lowered their price target on Replimune Group from $30.00 to $12.50 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of Replimune Group in a research note on Monday, September 30th. ValuEngine raised shares of Replimune Group from a “hold” rating to a “buy” rating in a report on Wednesday. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 target price on shares of Replimune Group in a report on Thursday, October 24th. Finally, Roth Capital upped their target price on shares of Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

In other Replimune Group news, CEO Robert Coffin sold 24,250 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $17.05, for a total value of $413,462.50. Also, CEO Jason P. Rhodes bought 15,000 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was acquired at an average cost of $3.42 per share, with a total value of $51,300.00. Over the last quarter, insiders have acquired 1,335,000 shares of company stock worth $18,016,500 and have sold 200,000 shares worth $3,395,500. Company insiders own 63.18% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in REPL. Squarepoint Ops LLC grew its stake in shares of Replimune Group by 34.6% in the third quarter. Squarepoint Ops LLC now owns 21,799 shares of the company’s stock worth $303,000 after acquiring an additional 5,599 shares during the period. Morgan Stanley raised its holdings in shares of Replimune Group by 793.0% during the second quarter. Morgan Stanley now owns 20,709 shares of the company’s stock valued at $304,000 after purchasing an additional 18,390 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Replimune Group by 211.3% during the second quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock valued at $338,000 after purchasing an additional 15,672 shares during the last quarter. Northern Trust Corp lifted its position in Replimune Group by 1.2% during the second quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock valued at $1,817,000 after purchasing an additional 1,437 shares during the period. Finally, State Street Corp lifted its position in Replimune Group by 6.0% during the third quarter. State Street Corp now owns 183,687 shares of the company’s stock valued at $2,553,000 after purchasing an additional 10,406 shares during the period. 56.99% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group stock opened at $13.88 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.85 and a quick ratio of 9.85. The business’s fifty day simple moving average is $14.72 and its two-hundred day simple moving average is $13.22. Replimune Group has a 12 month low of $8.88 and a 12 month high of $18.25.

Replimune Group (NASDAQ:REPL) last released its earnings results on Monday, November 11th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Sell-side analysts predict that Replimune Group will post -1.38 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Read More: Asset Allocation and Your Retirement

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.